Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal condition marked by chronic bowel pain or discomfort, as well as changes in abdominal motility. Despite its worldwide prevalence and clinical impact, the cause of IBS is unknown. Inflammation could play a fundamental role in...
Guardado en:
Autores principales: | Sahar M. El‑Haggar, Sahar K. Hegazy, Sherief M. Abd-Elsalam, Mostafa M. Bahaa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4ee74657a09b4c18aa2c8a8fc9d5b97d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effects of pentoxifylline on canine platelet aggregation
por: John M. Thomason, et al.
Publicado: (2021) -
The role of visceral hypersensitivity in the pathogenesis of irritable bowel syndrome
por: Alina A. Makarova, et al.
Publicado: (2021) -
Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
por: Wiktoria Feret, et al.
Publicado: (2021) -
Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic M, et al.
Publicado: (2021) -
Pentoxifylline therapy for patients with type 2 leprosy reactions: erythema nodosum leprosum in steroid-dependent cases
por: Khairuddin Djawad
Publicado: (2021)